ReviewCandidate immune biomarkers for radioimmunotherapy

- Newly available immune checkpoint blockers may synergize with radiotherapy.
- Multiple radioimmunotherapy (RI) combinations are assessed in early clinical trials.
- Immunological biomarkers (IB) are required for RI personalization.
- Candidate IB locate in the tumor microenvironment, genome and/or peripheral blood.

Newly available immune checkpoint blockers (ICBs), capable to revert tumor immune tolerance, are revolutionizing the anticancer armamentarium. Recent evidence also established that ionizing radiation (IR) could produce antitumor immune responses, and may as well synergize with ICBs. Multiple radioimmunotherapy combinations are thenceforth currently assessed in early clinical trials.Past examples have highlighted the need for treatment personalization, and there is an unmet need to decipher immunological biomarkers that could allow selecting patients who could benefit from these promising but expensive associations. Recent studies have identified potential predictive and prognostic immune assays at the cellular (tumor microenvironment composition), genomic (mutational/neoantigen load), and peripheral blood levels. Within this review, we collected the available evidence regarding potential personalized immune biomarker-directed radiation therapy strategies that might be used for patient selection in the era of radioimmunotherapy.